Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework
Published inEuropean journal of nuclear medicine and molecular imaging, vol. 48, no. 7, p. 2110-2120
Publication date2021-07
First online date2021-02-16
Abstract
Keywords
- Alzheimer’s disease
- Biomarker-based diagnosis
- Second-generation tau PET tracers
- Strategic roadmap
- Alzheimer Disease / diagnostic imaging
- Biomarkers
- Cohort Studies
- Humans
- Positron-Emission Tomography
- Tau Proteins
Funding
- FNS - IZSEZo [188355]
Citation (ISO format)
BISCHOF, Gérard N et al. Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework. In: European journal of nuclear medicine and molecular imaging, 2021, vol. 48, n° 7, p. 2110–2120. doi: 10.1007/s00259-020-05156-4
Main files (1)
Article (Published version)
Identifiers
- PID : unige:160859
- DOI : 10.1007/s00259-020-05156-4
- PMID : 33590274
- PMCID : PMC8175320
ISSN of the journal1619-7070